Genomic Landscape of ctDNA and Real-World Outcomes in Advanced Endometrial Cancer
This study is one of the largest cohorts of ctDNA currently reported in endometrial cancer. The presence of TP53 mutation and other comutations detected by ctDNA have a negative effect on outcomes. This report suggests that ctDNA analysis is feasible and could become a useful biomarker for endometrial cancer.
Authors
- Adrian Bubie (ORCID: https://orcid.org/0000-0001-8561-1801)
- Stéphanie Lheureux (ORCID: https://orcid.org/0000-0003-4405-5890)
- Brooke Grant (ORCID: https://orcid.org/0000-0001-9516-4515)
- Leylah Drusbosky (ORCID: https://orcid.org/0000-0002-9401-4600)
- Nicole Zhang (ORCID: https://orcid.org/0009-0001-2706-5838)
- Pamela Soberanis Pina (ORCID: https://orcid.org/0000-0002-9955-1245)
- G. Clark Haynes
- Keelia Clemens
Institutions
- University Health Network (CA)
- Princess Margaret Cancer Centre (CA)
- Guardant (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-10-17
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2105
- Citations
- 10
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.85